Published in Urology in April 2007 by Johns Hopkins University researcher Robert Getzenberg and his team, the paper reported that a novel protein in blood could be used as a sensitive test for
detecting early prostate cancer.
Not exact matches
An implant of genetically engineered skin cells has been designed to grow darker in colour when it
detects early breast,
prostate and colon
cancers
A new screening tool for
prostate cancer, the
prostate - specific antigen test, enabled doctors to
detect it
earlier in more men, and patients were flocking to hospitals for low doses of conventional photon radiation.
If
detected at
early stages the prognosis is quite favorable; however, aggressive forms of metastatic
prostate cancer spread primarily to the skeleton.
Edward Messing, the senior author of the study, says that PSA is capable of
detecting the disease
earlier, which could, in theory lead to fewer deaths from
prostate cancer.
«New three - in - one blood test opens door to precision medicine for
prostate cancer: Test picks out men for treatment,
detects early signs of resistance and monitors
cancer's evolution over time.»
A recently developed drug was significantly better at
detecting recurring
prostate cancer in
early stages, in research published in the August 2015 issue of The Journal of Nuclear Medicine.
Due to
prostate specific antigen testing (PSA), most of these
cancers are
detected early, long before they cause symptoms.
Prostate cancer and metastatic melanoma are both difficult
cancers to
detect early, and once
detected late they are nearly always impossible to cure, causing mortality within three years despite surgery and conventional therapies.
Anyone would want to have their
prostate cancer detected early.